The global next-generation antibody market is expected to reach US$ 12,050.13 million by 2028 from US$ 5,428.41 million in 2021; it is estimated to grow at a CAGR of 11.9% from 2021 to 2028.
Factors such as the increasing prevalence of cancer and growing demand for next-generation antibody therapeutics are boosting the market growth. However, complications associated with the manufacturing and approvals hamper the growth of the next-generation antibody market.
Next-generation antibodies are designed to be more specific and often more potent than traditional monoclonal antibodies. Next-generation antibody strategies are required to engineer a useful therapeutic combining antibody, payload, linker, and conjugation method while ensuring stability, targeted delivery, and limited off-target effects.
The next-generation antibody market is segmented on the basis of therapeutic area, technology, and geography. Based on therapeutic area, the market is bifurcated into oncology and autoimmune or inflammatory. The oncology segment held a larger share of the market in 2021. Moreover, the same segment is expected to register a higher CAGR during the forecast period. Based on technology, the next-generation antibody market is segmented into antibody-drug conjugates, bispecific antibodies, Fc engineered antibodies, antibody fragments and antibody-like proteins, and biosimilar antibody products. The antibody-drug conjugates segment is expected to hold the largest share of the market in the coming years. However, the bispecific antibodies segment is expected to register the highest CAGR from 2021 to 2028 due to the rise in usage of bispecific antibodies in the treatment of various diseases across the globe.
Globocan statistics, World Health Organization (WHO), International Agency for Research on Cancer (IARC), and Organization for Economic Co-operation and Development (OECD) are among the primary and secondary sources referred to while preparing the report on the next-generation antibody market.
Reasons to Buy
Factors such as the increasing prevalence of cancer and growing demand for next-generation antibody therapeutics are boosting the market growth. However, complications associated with the manufacturing and approvals hamper the growth of the next-generation antibody market.
Next-generation antibodies are designed to be more specific and often more potent than traditional monoclonal antibodies. Next-generation antibody strategies are required to engineer a useful therapeutic combining antibody, payload, linker, and conjugation method while ensuring stability, targeted delivery, and limited off-target effects.
The next-generation antibody market is segmented on the basis of therapeutic area, technology, and geography. Based on therapeutic area, the market is bifurcated into oncology and autoimmune or inflammatory. The oncology segment held a larger share of the market in 2021. Moreover, the same segment is expected to register a higher CAGR during the forecast period. Based on technology, the next-generation antibody market is segmented into antibody-drug conjugates, bispecific antibodies, Fc engineered antibodies, antibody fragments and antibody-like proteins, and biosimilar antibody products. The antibody-drug conjugates segment is expected to hold the largest share of the market in the coming years. However, the bispecific antibodies segment is expected to register the highest CAGR from 2021 to 2028 due to the rise in usage of bispecific antibodies in the treatment of various diseases across the globe.
Globocan statistics, World Health Organization (WHO), International Agency for Research on Cancer (IARC), and Organization for Economic Co-operation and Development (OECD) are among the primary and secondary sources referred to while preparing the report on the next-generation antibody market.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the next-generation antibody market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the global next-generation antibody market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the next-generation antibody market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution
Table of Contents
1. Introduction1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Next-generation Antibody Market - By Therapeutic Area
1.3.2 Global Next-generation Antibody Market - By Technology
1.3.3 Global Next-generation Antibody Market - By Geography
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Next-generation Antibody Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.2.2 Europe PEST Analysis
4.2.3 Asia Pacific PEST Analysis
4.2.4 Middle East and Africa PEST Analysis
4.2.5 South And Central America PEST Analysis
4.3 Experts Opinion
5. Next-generation Antibody Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Cancer
5.1.2 Growing Demand for Next-Generation Antibody Therapeutics
5.2 Market Restraints
5.2.1 Complications Associated with Manufacturing and Approvals
5.3 Market Opportunities
5.3.1 Proliferation of Biotechnology Industry in Developing Regions
5.4 Future Trends
5.4.1 Developments in Next-Generation Antibodies
5.5 Impact Analysis
6. Next-generation Antibody Market- Global Analysis
6.1 Global Next-generation Antibody Market Revenue Forecast and Analysis
6.2 Global Next-generation Antibody Market, By Geography - Forecast and Analysis
6.3 Market Positioning of Key Players
7. Global Next-generation Antibody Market Revenue and Forecasts To 2028- by Therapeutic Area
7.1 Overview
7.2 Global Next-generation Antibody Market, By Therapeutic Area, 2021 & 2028 (%)
7.3 Oncology
7.3.1 Overview
7.3.2 Oncology: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
7.4 Autoimmune or Inflammatory
7.4.1 Overview
7.4.2 Autoimmune or Inflammatory: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
8. Next-generation Antibody Market Revenue and Forecasts To 2028 - Technology
8.1 Overview
8.2 Global Next-generation Antibody Market Share by Segment - 2021 & 2028 (%)
8.3 Antibody-drug conjugates
8.3.1 Overview
8.3.2 Antibody-drug conjugates: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)
8.4 Bispecific antibodies
8.4.1 Overview
8.4.2 Bispecific antibodies: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)
8.5 Fc engineered antibodies
8.5.1 Overview
8.5.2 Fc engineered antibodies: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)
8.6 Antibody fragments and antibody-like proteins
8.6.1 Overview
8.6.2 Antibody fragments and antibody-like proteins: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)
8.7 Biosimilar antibody products
8.7.1 Overview
8.7.2 Biosimilar antibody products: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)
9. Next-generation Antibody Market Revenue and Forecasts to 2028 - Geographical Analysis
9.1 North America: Next-generation Antibody Market
9.1.1 Overview
9.1.2 North America: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
9.1.3 North America: Next-generation Antibody Market, by Therapeutic Area, 2019-2028 (US$ Million)
9.1.4 North America: Next-generation Antibody Market, by Technology, 2019-2028 (US$ Million)
9.1.5 North America: Next-generation Antibody Market, by Country, 2021 & 2028 (%)
9.1.5.1 US: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
9.1.5.1.1 Overview
9.1.5.1.2 US: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
9.1.5.1.3 US: Next-generation Antibody Market, by Therapeutic Area, 2019-2028 (US$ Million)
9.1.5.1.4 US: Next-generation Antibody Market, by Technology, 2019-2028 (US$ Million)
9.1.5.2 Canada: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
9.1.5.2.1 Overview
9.1.5.2.2 Canada: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
9.1.5.2.3 Canada: Next-generation Antibody Market, by Therapeutic Area, 2019-2028 (US$ Million)
9.1.5.2.4 Canada: Next-generation Antibody Market, by Technology, 2019-2028 (US$ Million)
9.1.5.3 Mexico: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
9.1.5.3.1 Overview
9.1.5.3.2 Mexico: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
9.1.5.3.3 Mexico: Next-generation Antibody Market, by Therapeutic Area, 2019-2028 (US$ Million)
9.1.5.3.4 Mexico: Next-generation Antibody Market, by Technology, 2019-2028 (US$ Million)
9.2 Europe: Next-generation Antibody Market
9.2.1 Overview
9.2.2 Europe: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
9.2.3 Europe: Next-generation Antibody Market, by Therapeutic Area - Revenue and Forecast to 2028 (US$ Million)
9.2.4 Europe: Next-generation Antibody Market, by Technology- Revenue and Forecast to 2028 (US$ Million)
9.2.5 Europe: Next-generation Antibody Market, by Country, 2021 & 2028 (%)
9.2.5.1 Germany: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.1.1 Overview
9.2.5.1.2 Germany: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.1.3 Germany: Next-generation Antibody Market, by Therapeutic Area - Revenue and Forecast to 2028 (US$ Million)
9.2.5.1.4 Germany: Next-generation Antibody Market, by Technology- Revenue and Forecast to 2028 (US$ Million)
9.2.5.2 France: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.2.1 Overview
9.2.5.2.2 France: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.2.3 France: Next-generation Antibody Market, by Therapeutic Area - Revenue and Forecast to 2028 (US$ Million)
9.2.5.2.4 France: Next-generation Antibody Market, by Technology- Revenue and Forecast to 2028 (US$ Million)
9.2.5.3 UK: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.3.1 Overview
9.2.5.3.2 UK: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.3.3 UK: Next-generation Antibody Market, by Therapeutic Area - Revenue and Forecast to 2028 (US$ Million)
9.2.5.3.4 UK: Next-generation Antibody Market, by Technology- Revenue and Forecast to 2028 (US$ Million)
9.2.5.4 Italy: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.4.1 Overview
9.2.5.4.2 Italy: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.4.3 Italy: Next-generation Antibody Market, by Therapeutic Area - Revenue and Forecast to 2028 (US$ Million)
9.2.5.4.4 Italy: Next-generation Antibody Market, by Technology- Revenue and Forecast to 2028 (US$ Million)
9.2.5.5 Spain: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.5.1 Overview
9.2.5.5.2 Spain: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.5.3 Spain: Next-generation Antibody Market, by Therapeutic Area - Revenue and Forecast to 2028 (US$ Million)
9.2.5.5.4 Spain: Next-generation Antibody Market, by Technology- Revenue and Forecast to 2028 (US$ Million)
9.2.5.6 Rest of Europe: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.6.1 Overview
9.2.5.6.2 Rest of Europe: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.6.3 Rest of Europe: Next-generation Antibody Market, by Therapeutic Area - Revenue and Forecast to 2028 (US$ Million)
9.2.5.6.4 Rest of Europe: Next-generation Antibody Market, by Technology- Revenue and Forecast to 2028 (US$ Million)
9.3 Asia Pacific Next-generation Antibody Market Revenue and Forecasts To 2028
9.3.1 Overview
9.3.2 Asia Pacific Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.3.3 Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
9.3.4 Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
9.3.5 Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028, By Country (%)
9.3.5.1 Japan: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.1.1 Overview
9.3.5.1.2 Japan: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.1.3 Japan: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
9.3.5.1.4 Japan: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
9.3.5.2 China: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.2.1 Overview
9.3.5.2.2 China: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.2.3 China: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
9.3.5.2.4 China: Next-generation Antibody Market Revenue and Forecasts to 2028, by Technology (US$ Million)
9.3.5.3 India Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.3.1 Overview
9.3.5.3.2 India: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.3.3 India: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
9.3.5.3.4 India: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
9.3.5.4 South Korea: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.4.1 Overview
9.3.5.4.2 South Korea: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.4.3 South Korea: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
9.3.5.4.4 South Korea: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
9.3.5.5 Australia: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.5.1 Overview
9.3.5.5.2 Australia: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.5.3 Australia: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
9.3.5.5.4 Australia: Next-generation Antibody Market Revenue and Forecasts to 2028, By Application (US$ Million)
9.3.5.6 Rest of Asia Pacific: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
9.3.5.6.1 Overview
9.3.5.6.2 Rest of Asia Pacific: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
9.3.5.6.3 Rest of Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
9.3.5.6.4 Rest of Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
9.4 Middle East & Africa Next-generation Antibody Market Revenue and Forecasts To 2028
9.4.1 Overview
9.4.2 Middle East & Africa Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.4.3 Middle East & Africa: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
9.4.4 Middle East & Africa: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
9.4.5 Middle East & Africa Next-generation Antibody Market Revenue and Forecasts to 2028, By Country (%)
9.4.5.1 UAE: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.4.5.1.1 Overview
9.4.5.1.2 UAE: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.4.5.1.3 UAE: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
9.4.5.1.4 UAE: Next-generation Antibody Market Revenue and Forecasts To 2028, By Technology (US$ Million)
9.4.5.2 Saudi Arabia: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.4.5.2.1 Overview
9.4.5.2.2 Saudi Arabia: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.4.5.2.3 Saudi Arabia: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
9.4.5.2.4 Saudi Arabia: Next-generation Antibody Market Revenue and Forecasts To 2028, By Technology (US$ Million)
9.4.5.3 South Africa: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.4.5.3.1 Overview
9.4.5.3.2 South Africa Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.4.5.3.3 South Africa: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
9.4.5.3.4 South Africa: Next-generation Antibody Market Revenue and Forecasts To 2028, By Technology (US$ Million)
9.4.5.4 Rest of Middle East and Africa: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.4.5.4.1 Overview
9.4.5.4.2 Rest of Middle East and Africa: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
9.4.5.4.3 Rest of Middle East & Africa: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
9.4.5.4.4 Rest of Middle East & Africa: Next-generation Antibody Market Revenue and Forecasts To 2028, By Technology (US$ Million)
9.5 South and Central America Next-generation Antibody Market Revenue and Forecasts To 2028
9.5.1 Overview
9.5.2 South and Central America: Next-generation Antibody Market - Revenue and Forecast to 2028 (USD Million)
9.5.3 South and Central America: Next-generation Antibody Market, by Therapeutic Area, 2019-2028 (USD Million)
9.5.4 South and Central America: Next-generation Antibody Market, by Technology, 2019-2028 (USD Million)
9.5.5 South and Central America: Next-generation Antibody Market, by Country, 2021 & 2028 (%)
9.5.5.1 Brazil: Next-generation Antibody Market - Revenue and Forecast to 2028 (USD Million)
9.5.5.1.1 Overview
9.5.5.1.2 Brazil: Next-generation Antibody Market - Revenue and Forecast to 2028 (USD Million)
9.5.5.1.3 Brazil: Next-generation Antibody Market, by Therapeutic Area, 2019-2028 (USD Million)
9.5.5.1.4 Brazil: Next-generation Antibody Market, by Technology, 2019-2028 (USD Million)
9.5.5.2 Argentina: Next-generation Antibody Market - Revenue and Forecast to 2028 (USD Million)
9.5.5.2.1 Overview
9.5.5.2.2 Argentina: Next-generation Antibody Market - Revenue and Forecast to 2028 (USD Million)
9.5.5.2.3 Argentina: Next-generation Antibody Market, by Therapeutic Area, 2019-2028 (USD Million)
9.5.5.2.4 Argentina: Next-generation Antibody Market, by Technology, 2019-2028 (USD Million)
9.5.5.3 Rest of South & Central America: Next-generation Antibody Market - Revenue and Forecast to 2028 (USD Million)
9.5.5.3.1 Overview
9.5.5.3.2 Rest of South & Central America: Next-generation Antibody Market - Revenue and Forecast to 2028 (USD Million)
9.5.5.3.3 Rest of South & Central America: Next-generation Antibody Market, by Therapeutic Area, 2019-2028 (USD Million)
9.5.5.3.4 Rest of South & Central America: Next-generation Antibody Market, by Technology, 2019-2028 (USD Million)
10. Impact Of COVID-19 Pandemic on Next-generation Antibody Market
10.1 North America: Impact Assessment of COVID-19 Pandemic
10.2 Europe: Impact Assessment of COVID-19 Pandemic
10.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
10.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
10.5 South and Central America: Impact Assessment of COVID-19 Pandemic
11. Next-generation Antibody Market-Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Next-generation Antibody Market (%)
11.3 Organic Developments
11.3.1 Overview
11.4 Inorganic Developments
11.4.1 Overview
12. Company Profiles
12.1 F. HOFFMANN-LA ROCHE LTD
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Kyowa Kirin Co., Ltd
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Seagen Inc
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 ImmunoGen, Inc
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Takeda Pharmaceutical Company Limited
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Amgen Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Pfizer Inc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Catalent Inc
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 AstraZeneca
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Xencor
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Publisher
13.2 Glossary of TermsList of Tables
Table 1. New Cancer Cases Registered Worldwide, 2020
Table 2. North America Next-generation Antibody Market, by Therapeutic Area - Revenue and Forecast to 2028 (US$ Million)
Table 3. North America Next-generation Antibody Market, by Technology- Revenue and Forecast to 2028 (US$ Million)
Table 4. US Next-generation Antibody Market, by Therapeutic Area - Revenue and Forecast to 2028 (US$ Million)
Table 5. US Next-generation Antibody Market, by Technology- Revenue and Forecast to 2028 (US$ Million)
Table 6. Canada: Next-generation Antibody Market, by Therapeutic Area - Revenue and Forecast to 2028 (US$ Million)
Table 7. Canada Next-generation Antibody Market, by Technology- Revenue and Forecast to 2028 (US$ Million)
Table 8. Mexico: Next-generation Antibody Market, by Therapeutic Area - Revenue and Forecast to 2028 (US$ Million)
Table 9. Mexico Next-generation Antibody Market, by Technology- Revenue and Forecast to 2028 (US$ Million)
Table 10. Europe: Next-generation Antibody Market, by Therapeutic Area - Revenue and Forecast to 2028 (US$ Million)
Table 11. Europe: Next-generation Antibody Market, by Technology- Revenue and Forecast to 2028 (US$ Million)
Table 12. Germany: Next-generation Antibody Market, by Therapeutic Area - Revenue and Forecast to 2028 (US$ Million)
Table 13. Germany: Next-generation Antibody Market, by Technology- Revenue and Forecast to 2028 (US$ Million)
Table 14. France: Next-generation Antibody Market, by Therapeutic Area - Revenue and Forecast to 2028 (US$ Million)
Table 15. France: Next-generation Antibody Market, by Technology- Revenue and Forecast to 2028 (US$ Million)
Table 16. UK: Next-generation Antibody Market, by Therapeutic Area - Revenue and Forecast to 2028 (US$ Million)
Table 17. UK: Next-generation Antibody Market, by Technology- Revenue and Forecast to 2028 (US$ Million)
Table 18. Italy: Next-generation Antibody Market, by Therapeutic Area - Revenue and Forecast to 2028 (US$ Million)
Table 19. Italy: Next-generation Antibody Market, by Technology- Revenue and Forecast to 2028 (US$ Million)
Table 20. Spain: Next-generation Antibody Market, by Therapeutic Area - Revenue and Forecast to 2028 (US$ Million)
Table 21. Spain: Next-generation Antibody Market, by Technology- Revenue and Forecast to 2028 (US$ Million)
Table 22. Rest of Europe: Next-generation Antibody Market, by Therapeutic Area - Revenue and Forecast to 2028 (US$ Million)
Table 23. Rest of Europe: Next-generation Antibody Market, by Technology- Revenue and Forecast to 2028 (US$ Million)
Table 24. Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million).
Table 25. Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 26. Japan: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
Table 27. Japan: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 28. China: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
Table 29. China: Next-generation Antibody Market Revenue and Forecasts to 2028, by Technology (US$ Million)
Table 30. India: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
Table 31. India: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 32. South Korea: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
Table 33. South Korea: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 34. Australia: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
Table 35. Australia: Next-generation Antibody Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 36. Rest of Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
Table 37. Rest of Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 38. Middle East & Africa: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million).
Table 39. Middle East & Africa: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 40. UAE: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
Table 41. UAE: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 42. Saudi Arabia: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
Table 43. Saudi Arabia: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 44. South Africa Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
Table 45. South Africa: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 46. Rest of Middle East & Africa: Next-generation Antibody Market Revenue and Forecasts to 2028, By Therapeutic Area (US$ Million)
Table 47. Rest of Middle East & Africa: Next-generation Antibody Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 48. South and Central America: Next-generation Antibody Market, by Therapeutic Area - Revenue and Forecast to 2028 (US$ Million)
Table 49. South and Central America: Next-generation Antibody Market, by Technology - Revenue and Forecast to 2028 (US$ Million)
Table 50. Brazil: Next-generation Antibody Market, by Therapeutic Area - Revenue and Forecast to 2028 (US$ Million)
Table 51. Brazil: Next-generation Antibody Market, by Technology - Revenue and Forecast to 2028 (US$ Million)
Table 52. Argentina: Next-generation Antibody Market, by Therapeutic Area - Revenue and Forecast to 2028 (US$ Million)
Table 53. Argentina: Next-generation Antibody Market, by Technology - Revenue and Forecast to 2028 (US$ Million)
Table 54. Rest of South & Central America: Next-generation Antibody Market, by Therapeutic Area - Revenue and Forecast to 2028 (US$ Million)
Table 55. Rest of South & Central America: Next-generation Antibody Market, by Technology - Revenue and Forecast to 2028 (US$ Million)
Table 56. Organic Developments in the Next-generation Antibody Market
Table 57. Inorganic Developments in the Next-generation Antibody Market
Table 58. Glossary of Terms
List of Figures
Figure 1. Next-generation Antibody Market Segmentation
Figure 2. Next-generation Antibody Market, By Region
Figure 3. Global Next-generation Antibody Market Overview
Figure 4. Oncology Segment Held Largest Share of Therapeutic Area Segment in Next-generation Antibody Market
Figure 5. Asia Pacific is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. Next-generation Antibody Market, by Geography (US$ Million)
Figure 7. Global Next-generation Antibody Market- Leading Country Markets (US$ Million)
Figure 8. Global Next-generation Antibody Market, Industry Landscape
Figure 9. North America: PEST Analysis
Figure 10. Europe: PEST Analysis
Figure 11. Asia Pacific: PEST Analysis
Figure 12. Middle East and Africa: PEST Analysis
Figure 13. South And Central America: PEST Analysis
Figure 14. Experts Opinion
Figure 15. Next-Generation Antibody Market Impact Analysis of Driver and Restraints
Figure 16. Global Next-generation Antibody Market- Revenue Forecast and Analysis - 2021 - 2028
Figure 17. Global Next-generation Antibody Market - By Geography Forecast and Analysis - 2021 - 2028
Figure 18. Market Positioning of Key Players in Global Next-generation Antibody Market
Figure 19. Global Next-generation Antibody Market, by Therapeutic Area, 2021 & 2028 (%)
Figure 20. Oncology: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 21. Autoimmune or Inflammatory: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 22. Global Next-generation Antibody Market Share by Segment - 2021 & 2028 (%)
Figure 23. Antibody-drug conjugates: Next-generation Antibody Market Revenue and Forecasts To 2028 (US$ Million)
Figure 24. Bispecific antibodies: Next-generation Antibody Market Revenue and Forecasts To 2028 (US$ Million)
Figure 25. Fc engineered antibodies: Next-generation Antibody Market Revenue and Forecasts To 2028 (US$ Million)
Figure 26. Antibody fragments and antibody-like proteins: Next-generation Antibody Market Revenue and Forecasts To 2028 (US$ Million)
Figure 27. Biosimilar antibody products: Next-generation Antibody Market Revenue and Forecasts To 2028 (US$ Million)
Figure 28. North America: Next-generation Antibody Market, by Key Country - Revenue (2021) (US$ Million)
Figure 29. North America Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)
Figure 30. North America: Next-generation Antibody Market, by Country, 2021 & 2028 (%)
Figure 31. US: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
Figure 32. Canada: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
Figure 33. Mexico: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
Figure 34. Europe: Next-generation Antibody Market, by Key Country - Revenue (2021) (US$ Million)
Figure 35. Europe: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)
Figure 36. Europe: Next-generation Antibody Market, by Country, 2021 & 2028 (%)
Figure 37. Germany: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
Figure 38. France: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
Figure 39. UK: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
Figure 40. Italy: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
Figure 41. Spain: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
Figure 42. Rest of Europe: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
Figure 43. Asia Pacific Next-generation Antibody Market Overview, by Country (2021)
Figure 44. Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 45. Asia Pacific: Next-generation Antibody Market Revenue and Forecasts to 2028, By Country (%)
Figure 46. Japan: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 47. China: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 48. India: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 49. South Korea: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 50. Australia: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 51. Rest of Asia Pacific: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
Figure 52. Middle East & Africa Next-generation Antibody Market Revenue Overview, by Country, 2021 (US$ Million)
Figure 53. Middle East & Africa Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 54. Middle East & Africa Next-generation Antibody Market Revenue and Forecasts to 2028, By Country (%)
Figure 55. UAE: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 56. Saudi Arabia: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 57. South Africa: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 58. Rest of Middle East and Africa: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 59. South and Central America: Next-generation Antibody Market, by Key Country - Revenue (2021) (US$ Million)
Figure 60. South and Central America Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)
Figure 61. South and Central America: Next-generation Antibody Market, by Country, 2021 & 2028 (%)
Figure 62. Brazil: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
Figure 63. Argentina: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
Figure 64. Rest of South & Central America: Next-generation Antibody Market - Revenue and Forecast to 2028 (US$ Million)
Figure 65. Impact of COVID-19 Pandemic in North American Country Markets
Figure 66. Impact of COVID-19 Pandemic in European Country Markets
Figure 67. Impact of COVID-19 Pandemic in Asia Pacific Country Markets
Figure 68. Impact of COVID-19 Pandemic in Middle East and Africa Country Markets
Figure 69. Impact of COVID-19 Pandemic in South and Central American Countries
Figure 70. Growth Strategies in the Next-generation Antibody Market (%)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- F. HOFFMANN-LA ROCHE LTD.
- Kyowa Kirin Co., Ltd.
- Seagen Inc.
- ImmunoGen, Inc.
- Takeda Pharmaceutical Company Limited
- Amgen Inc.
- Pfizer Inc.
- Catalent Inc
- AstraZeneca
- Xencor
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 181 |
| Published | January 2022 |
| Forecast Period | 2021 - 2028 |
| Estimated Market Value ( USD | $ 5468.41 million |
| Forecasted Market Value ( USD | $ 12050.13 million |
| Compound Annual Growth Rate | 11.9% |
| Regions Covered | Global |
